MatriSys Bioscience

MatriSys Bioscience is a private, pre-revenue biotech company leveraging a proprietary discovery platform to develop topical live biotherapeutics from beneficial skin bacteria. Its lead program targets atopic dermatitis, with additional candidates for acne, Netherton syndrome, and other disorders, addressing a significant unmet need in dermatology. The company is led by a seasoned team with strong scientific roots in skin immunology and microbiome research from UCSD and extensive drug development experience. MatriSys aims to reduce reliance on steroids and immunosuppressants by restoring the natural skin microbiome.

Proprietary discovery platform that identifies, isolates, and optimizes beneficial bacterial strains derived from the healthy human skin microbiome to develop topical live biotherapeutic products for restoring skin homeostasis.

MatriSys competes in the crowded dermatology market against dominant players selling steroids, biologics (e.g., Dupixent), and JAK inhibitors. Its direct competitors are other early-stage companies developing skin microbiome-based therapies, such as Azitra, S-Biomedic, and others, creating a race to clinical validation. Its differentiation lies in its strong foundational science from the Gallo lab and a focus on topical application.